{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-22-029279","form_type":"8-K","ticker":"CRVO","cik":"0001053691","company_name":"CervoMed Inc.","filed_at":"2022-12-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:49.435342+00:00","generated_at":"2026-06-21T03:05:55.120685+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Diffusion settles proxy contest with LifeSci; may appoint director if no deal by July 2023","bullets":["LifeSci Special Opportunities withdraws its director nominees and will vote for Diffusion's slate at Dec 30 annual meeting.","If no strategic transaction (e.g., sale, merger) completed by July 1, 2023, Diffusion must appoint a LifeSci-designated director.","LifeSci, owning ~4.8% of DFFN shares, agrees to standstill and voting commitments through at least Dec 31, 2024.","Diffusion to reimburse LifeSci up to $50,000 for expenses related to nomination and negotiation."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-22-029279","json":"https://secwatch.observer/filing/0001437749-22-029279.json","markdown":"https://secwatch.observer/filing/0001437749-22-029279.md","text":"https://secwatch.observer/filing/0001437749-22-029279.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1053691/000143774922029279/0001437749-22-029279-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1053691/000143774922029279/dffn20221215_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T03:05:55.120685+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"177ac10869f7354d99c046ee573e0e76aa8ebb7d","claim":"CervoMed Inc. entered into Agreement with LifeSci Special Opportunities Master Fund Ltd. and certain of its affiliates (effective 2022-12-15).","evidence_excerpt":"On December 15, 2022, Diffusion Pharmaceuticals Inc. (the “ Company ”) entered into a binding settlement agreement (the “ Agreement ”) with LifeSci Special Opportunities Master Fund Ltd. and certain of its affiliates (collectively, “ LifeSci Special Opportunities ”)","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1053691/000143774922029279/0001437749-22-029279-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"settlement"},{"label":"Counterparty","value":"LifeSci Special Opportunities Master Fund Ltd. and certain of its affiliates"},{"label":"Effective","value":"2022-12-15"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}